Key secondary endpoint ( cardiovascular death , myocardial infarction , stroke ) rates were 13.4 % with vorapaxar and 14.9 % with placebo ( HR 0.89 , 95 % CI 0.74-1 .07 ) , with no interaction ( p = 0.58 ) .